Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Equities research analysts at Zacks Research reduced their FY2027 earnings per share (EPS) estimates for shares of Surmodics in a report issued on Thursday, March 20th. Zacks Research analyst D. Dey now forecasts that the company will post earnings per share of $0.83 for the year, down from their prior forecast of $0.84. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share.
Surmodics (NASDAQ:SRDX - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.
A number of other research analysts have also recently issued reports on the company. Needham & Company LLC reiterated a "hold" rating on shares of Surmodics in a research note on Thursday, January 30th. Lake Street Capital upgraded Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price objective for the company in a research note on Friday, March 7th. Finally, StockNews.com started coverage on Surmodics in a research note on Monday, February 3rd. They set a "hold" rating for the company. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $50.00.
Read Our Latest Report on SRDX
SRDX opened at $30.38 on Monday. The business has a 50 day moving average of $33.44 and a 200-day moving average of $37.03. The stock has a market cap of $434.31 million, a PE ratio of -30.08 and a beta of 1.19. Surmodics has a 52 week low of $25.17 and a 52 week high of $42.44. The company has a quick ratio of 4.29, a current ratio of 5.45 and a debt-to-equity ratio of 0.26.
A number of institutional investors and hedge funds have recently modified their holdings of SRDX. Principal Financial Group Inc. bought a new stake in shares of Surmodics in the 3rd quarter worth $1,190,000. Quest Partners LLC grew its holdings in shares of Surmodics by 107,100.0% in the third quarter. Quest Partners LLC now owns 1,072 shares of the company's stock worth $42,000 after acquiring an additional 1,071 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Surmodics by 1.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 116,311 shares of the company's stock worth $4,511,000 after acquiring an additional 1,491 shares during the period. Algert Global LLC grew its holdings in shares of Surmodics by 29.9% in the third quarter. Algert Global LLC now owns 17,820 shares of the company's stock worth $691,000 after acquiring an additional 4,098 shares during the period. Finally, Longfellow Investment Management Co. LLC bought a new stake in shares of Surmodics in the third quarter worth $67,000. Institutional investors own 96.63% of the company's stock.
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Surmodics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.
While Surmodics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.